Crossmark

Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients

Crossref DOI link: https://doi.org/10.1016/j.htct.2024.04.125

Published Print: 2024-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Bakr, Salwa https://orcid.org/0000-0001-6345-6097
Salem, Karem Mohamed

Rashed, Ahmed Mohammed

Tantawy, Mohamed E A

Elsary, Asmaa Younis

Shamardl, Hanan Abdelmoneam https://orcid.org/0000-0001-7042-5731
Ezzat, Eman Mahmoud
License Information

Text and Data Mining valid from 2024-11-01

Text and Data Mining valid from 2024-11-01

Version of Record valid from 2024-08-09
More Information

This article is maintained by: Elsevier

Article Title: Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2024.04.125

Content Type: article

Copyright: © 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below